ReviewCancer metastasis reviews2026
Before the seeds arrive: pre-metastatic niche orchestration in bladder cancer.
Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic relapse remains a major cause of mortality in bladder cancer (BCa), yet the biological processes that prepare distant organs for tumor colonization before overt metastasis remain incompletely understood. The pre-metastatic niche (PMN) provides a framework for viewing metastasis as a systemic process in which tumor-derived signals reshape distant immune, stromal, vascular, lymphatic, and metabolic environments before cancer-cell arrival. In BCa, some of the strongest disease-specific evidence implicates extracellular vesicle (EV)-mediated communication, including effects on lymphangiogenesis, vascular permeability, myeloid suppression, stromal crosstalk, and metabolic reprogramming. Additional contributions from myeloid-derived suppressor cells, macrophages, fibroblasts, neutrophil extracellular traps, chemokine networks, and metabolic adaptation may further promote niche permissiveness, although direct BCa evidence remains uneven across mechanisms and metastatic organs. Organotropism to lymph nodes, lung, liver, and bone may reflect the convergence of tumor-intrinsic programs, EV surface molecules, chemokine gradients, and tissue-specific receptivity. Clinically, PMN-associated biomarkers could complement minimal residual disease (MRD) assessment by integrating ctDNA with plasma and urinary EVs and immune, stromal, and metabolic signals. However, such approaches remain investigational and require prospective validation. This review critically evaluates current BCa-specific and cross-cancer evidence, highlights key mechanistic and translational gaps, and proposes a hypothesis-generating MRD-PMN framework for future surveillance and metastatic-interception studies.
Indexed as
Identifiers
42911273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.